Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT07269639 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Large B-Cell Lymphoma (LBCL)

Interventions

DRUG: Golcadomide + Poseltinib + Rituximab

Sponsor

Seoul National University Hospital